Skip to main content
Log in

Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density

  • Correspondence
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S et al (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85(9):605–609

    Article  CAS  PubMed  Google Scholar 

  2. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M et al (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86(1):23–30

    Article  CAS  PubMed  Google Scholar 

  3. Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590

    Article  CAS  PubMed  Google Scholar 

  4. Naithani R, Seth T, Tandon N, Chandra J, Pati H, Saxena R et al (2017) Fractures and low bone mineral density in patients with beta thalassemia major. Indian J Hematol Blood Transfus. doi:10.1007/s12288-017-0820-1

    Google Scholar 

  5. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate induced hypocalcaemia: report of 3 cases and review of literature. Endocr Pract 12:48–53

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

Financial support was obtained from Shantha Biotech for DXA scans and zoledronic acid for these patients.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rahul Naithani.

Ethics declarations

Conflict of interests

All the authors declares that they have no conflict of interests.

Informed Consent

Informed consent was obtained from all individual participants included in the study. This was part of DM thesis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Naithani, R., Seth, T., Tandon, N. et al. Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density. Indian J Hematol Blood Transfus 34, 345–346 (2018). https://doi.org/10.1007/s12288-017-0858-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-017-0858-0

Keywords

Navigation